中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2010年
7期
451-455
,共5页
徐泽锋%秦铁军%张悦%刘凯奇%郝玉书%肖志坚
徐澤鋒%秦鐵軍%張悅%劉凱奇%郝玉書%肖誌堅
서택봉%진철군%장열%류개기%학옥서%초지견
骨髓增生异常综合征%环孢素%沙利度胺%疗效%不良反应
骨髓增生異常綜閤徵%環孢素%沙利度胺%療效%不良反應
골수증생이상종합정%배포소%사리도알%료효%불량반응
Myelodysplastic syndromes%Cyclosporine A%Thalidomide%Treatment outcome%Side-effects
目的 评价环孢素(CsA)联合沙利度胺治疗骨髓增生异常综合征(MDS)的疗效与不良反应.方法 37例WHO分型(2001)为难治性血细胞减少伴有多系发育异常(RCMD)和难治性贫血伴有原始细胞过多-I(RAEB-I)患者接受CsA联合沙利度胺治疗,CsA起始剂量为3 mg·kg-1·d-1,2周后检测血CsA浓度,根据血药浓度调整用药剂量,使CsA谷浓度维持在100~200μg/L,沙利度胺起始剂量为50 mg/d,1周内增至100 mg/d,无明显不良反应则最大剂量为200 mg/d.依据国际工作组2006疗效标准评价血液学疗效,按美国国立肿瘤研究所常见毒性标准(version 3.0)判定不良反应.同时观察有效持续时间和总体生存率.结果 患者中红系反应率为51.4%(37例中19例);中性粒细胞反应率为21.2%(33例中7例);血小板反应率为31.0%(29例中9例);在依赖输血的32例患者中,15例(46.9%)脱离输血.红系反应中位持续时间为88(4~108)周,血小板反应中位持续时间为78(8~84+)周,中性粒细胞反应中位持续时间为78(10~84+)周.中位随访时间为29(4~103)个月,中位生存时间为52个月.不良反应包括1~2级肝肾损害、便秘、嗜睡、头昏、水肿、皮疹、麻木感,经对症治疗后均好转,所有患者未出现3级以上不良反应.结论 CsA联合沙利度胺治疗MDS能有效改善患者贫血,不良反应轻.
目的 評價環孢素(CsA)聯閤沙利度胺治療骨髓增生異常綜閤徵(MDS)的療效與不良反應.方法 37例WHO分型(2001)為難治性血細胞減少伴有多繫髮育異常(RCMD)和難治性貧血伴有原始細胞過多-I(RAEB-I)患者接受CsA聯閤沙利度胺治療,CsA起始劑量為3 mg·kg-1·d-1,2週後檢測血CsA濃度,根據血藥濃度調整用藥劑量,使CsA穀濃度維持在100~200μg/L,沙利度胺起始劑量為50 mg/d,1週內增至100 mg/d,無明顯不良反應則最大劑量為200 mg/d.依據國際工作組2006療效標準評價血液學療效,按美國國立腫瘤研究所常見毒性標準(version 3.0)判定不良反應.同時觀察有效持續時間和總體生存率.結果 患者中紅繫反應率為51.4%(37例中19例);中性粒細胞反應率為21.2%(33例中7例);血小闆反應率為31.0%(29例中9例);在依賴輸血的32例患者中,15例(46.9%)脫離輸血.紅繫反應中位持續時間為88(4~108)週,血小闆反應中位持續時間為78(8~84+)週,中性粒細胞反應中位持續時間為78(10~84+)週.中位隨訪時間為29(4~103)箇月,中位生存時間為52箇月.不良反應包括1~2級肝腎損害、便祕、嗜睡、頭昏、水腫、皮疹、痳木感,經對癥治療後均好轉,所有患者未齣現3級以上不良反應.結論 CsA聯閤沙利度胺治療MDS能有效改善患者貧血,不良反應輕.
목적 평개배포소(CsA)연합사리도알치료골수증생이상종합정(MDS)적료효여불량반응.방법 37례WHO분형(2001)위난치성혈세포감소반유다계발육이상(RCMD)화난치성빈혈반유원시세포과다-I(RAEB-I)환자접수CsA연합사리도알치료,CsA기시제량위3 mg·kg-1·d-1,2주후검측혈CsA농도,근거혈약농도조정용약제량,사CsA곡농도유지재100~200μg/L,사리도알기시제량위50 mg/d,1주내증지100 mg/d,무명현불량반응칙최대제량위200 mg/d.의거국제공작조2006료효표준평개혈액학료효,안미국국립종류연구소상견독성표준(version 3.0)판정불량반응.동시관찰유효지속시간화총체생존솔.결과 환자중홍계반응솔위51.4%(37례중19례);중성립세포반응솔위21.2%(33례중7례);혈소판반응솔위31.0%(29례중9례);재의뢰수혈적32례환자중,15례(46.9%)탈리수혈.홍계반응중위지속시간위88(4~108)주,혈소판반응중위지속시간위78(8~84+)주,중성립세포반응중위지속시간위78(10~84+)주.중위수방시간위29(4~103)개월,중위생존시간위52개월.불량반응포괄1~2급간신손해、편비、기수、두혼、수종、피진、마목감,경대증치료후균호전,소유환자미출현3급이상불량반응.결론 CsA연합사리도알치료MDS능유효개선환자빈혈,불량반응경.
Objective To explore the efficiency and side-effects of the combination of cyclosporine A ( CsA) and thalidomide in patients with myelodysplastic syndromes( MDS). Methods A total of thirty-seven patients with MDS-RCMD or-RAEB- I were treated with CsA in combination with thalidomide. The initial CsA dose of 3 mg kg-1 d-1 was administered, all patients had their CsA blood concentration concurrently monitored until it reached and maintained between 100 and 200 μg/L. The initial dose of thalidomide was 50 mg/d, with increasing dose of 50 mg every week until the maximum of 200 mg/d. The hematological response was assessed according to the modified criteria of the International Working Group, and adverse events were graded with the Common Toxicity Criteria (v3.0) of the National Cancer Institute. The response duration and overall survival of the patients were also observed. Results 19/37 cases (51. 4% ) achieved hematologic improvement(HI)-erythroid response(HI-E), 9/29 cases (31.0%) Hi-platelet response (HI-P) and 7/33 cases (21.2%) HI-neutrophil response (HI-N). 15 of 32 transfusion-dependent patients (46.9% ) achieved transfusion independence. The median response duration of HI-E, HI-P and HI-N were 88 (4 - 88) weeks, 78(8 -846+ ) weeks and 78 (10-84+ ) weeks respectively. The median overall survival was 52 months on a 29(4-103) months median follow-up. Some patients developed grades I - II hepatic or nephritic impairment, constipation, lethargy, dizziness, edema, rashes or numbness, and all were tolerable and reversible. No grade Ⅲ or severer adverse events were observed. Conclusion CsA in combination with thalidomide appears to be effective mainly in inducing HI-E and relatively well-tolerated for the treatment of patients with MDS.